A phase I clinical trial on intratumoral injection of autologous CD1c (BDCA-1)+ / CD141 (BDCA-3)+ myeloid dendritic cells in combination with talimogene laherparepvec (T-VEC) in patients with advanced pretreated melanoma

Activiteit: Talk or presentation at a conference


Mini oral presentation in the "Investigational Immunotherapy" session
Periode17 sep 2021
EvenementstitelESMO Congress 2021
LocatieParis, France
Mate van erkenningInternational